U.S. markets open in 6 hours 51 minutes

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
22.21-0.01 (-0.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close22.22
Open22.18
Bid12.04 x 800
Ask23.00 x 1400
Day's Range21.83 - 22.67
52 Week Range20.01 - 56.59
Volume275,796
Avg. Volume395,638
Market Cap1.704B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 16, 2021 - Aug 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
    Business Wire

    ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

    LAUSANNE, Switzerland, Jun 11, 2021--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterday's Annual General Meeting (AGM).

  • ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
    Business Wire

    ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

    ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that abstracts on camidanlumab tesirine (Cami) and ZYNLONTA™ (loncastuximab tesirine-lpyl) have been selected for presentation at the 16th Annual International Conference on Malignant Lymphoma (ICML), which is being held virtually June 18-22, 2021.

  • ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
    Business Wire

    ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

    ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated clinical data from the ZYNLONTA™ (loncastuximab tesirine-lpyl) Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually J